Gerresheimer, a manufacturer for the pharma and life science industry, will invest more than $88 million in expanding its manufacturing operations in Peachtree City, creating over 200 new jobs for Fayette County.
Futura Medical plc has extended until January 2029 its exclusive licensing agreement with Cooper Consumer Health to commercialise Eroxon, the Company's topical, gel-based Erectile Dysfunction treatment.
EirGen Pharma has announced the commencement of works in its new plant in the IDA Industrial Estate, including a €20 million internal refit and additional Plant rooms expanding its Oral Solid Dose manufacturing and packaging capabilities.
Isomorphic Labs have announced that it has entered into a strategic research collaboration with Eli Lilly and Company and a strategic research collaboration with Novartis to discover small molecule therapeutics against three undisclosed targets.
WuXi AppTec have announced the commissioning of two new peptide manufacturing plants, one at its Changzhou facility and another at the new Taixing site in China.
Bayer announced last week that the UK’s MHRA has authorised its 52mg levonorgestrel releasing intrauterine system Mirena for extended use up to eight years for contraception in the UK.
Novartis recently announced that it has received approval from the US FDA for commercial manufacturing of Pluvicto at its new large-scale, state-of-the-art radioligand therapy (RLT) manufacturing facility in Indianapolis, Indiana, United States.
Eli Lilly and Company have announced LillyDirect, a new digital healthcare experience for patients in the U.S. living with obesity, migraine and diabetes.
Shionogi B.V., the European subsidiary of SHIONOGI & Co., Ltd. have announced that they have signed a distribution agreement with Swedish Orphan Biovitrum AB, Sobi, for Fetcroja covering 13 countries in Central & Eastern Europe.
Organon have announced an agreement with Eli Lilly and Company to become the sole distributor and promoter for the migraine medicines Emgality (galcanezumab) and RAYVOW (lasmiditan) in Europe.
The National Institute for Health and Care Excellence (NICE) has issued its Final Draft Guidance (FDG) recommending empagliflozin (Jardiance) as an option for the treatment of eligible adults with chronic kidney disease.
